Bioregenx (BRGX) Gross Margin (2023 - 2026)

Bioregenx's Gross Margin history runs 4 years deep, the most recent figure standing at 81.72% for Q1 2026.

• On a quarterly basis, Gross Margin rose 291.0% year-over-year to 81.72% in Q1 2026; TTM through Mar 2026 was 81.96%, a 916.0% increase from a year earlier, with the FY2025 full-year figure at 81.08%, up 1734.0% from the prior year.
• Gross Margin slipped to 81.72% in Q1 2026 per BRGX's latest filing, from 83.51% in the prior quarter.
• Across five years, Gross Margin topped out at 83.68% in Q3 2025 and bottomed at 39.6% in Q4 2023.
• The 4-year median for Gross Margin is 71.39% (2023), against an average of 71.17%.
• Biggest YoY gain for Gross Margin was 3013 bps in 2024; the steepest drop was 1313 bps in 2024.
• Year by year, Gross Margin stood at 39.6% in 2023, then soared by 76 bps to 69.73% in 2024, then gained by 20 bps to 83.51% in 2025, then fell by 2 bps to 81.72% in 2026.
• Per Business Quant, the three latest BRGX Gross Margin figures stand at 81.72% (Q1 2026), 83.51% (Q4 2025), and 83.68% (Q3 2025).